<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment and prognosis of Waldenström macroglobulinemia
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment and prognosis of Waldenström macroglobulinemia
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment and prognosis of Waldenström macroglobulinemia
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stephen M Ansell, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            S Vincent Rajkumar, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rebecca F Connor, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 26, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H54286892">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The term "macroglobulinemia" refers to the production of excess immunoglobulin M (IgM) monoclonal protein that occurs in certain clonal lymphoproliferative disorders and plasma cell dyscrasias. Waldenström macroglobulinemia (WM) is a distinct clinicopathologic entity demonstrating both:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lymphoplasmacytic lymphoma (LPL) in the bone marrow, and
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elevated levels of IgM in the blood (IgM monoclonal gammopathy, termed "macroglobulinemia")
        </p>
        <p>
        </p>
        <p>
         Patients may be asymptomatic or present with symptoms related to the infiltration of the lymph nodes and spleen or the effects of monoclonal IgM in the blood.
        </p>
        <p>
         The treatment and prognosis of WM will be reviewed here. The clinical manifestations and diagnosis of this disorder are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6657.html" rel="external">
          "Epidemiology, pathogenesis, clinical manifestations, and diagnosis of Waldenström macroglobulinemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4768.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H779381757">
         <span class="h1">
          PRETREATMENT EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial evaluation of patients with WM must establish the diagnosis, the extent of disease, the presence of associated conditions, and the performance status of the patient.
        </p>
        <p>
         Particular attention should be paid to the following in the history and physical examination:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptoms of hyperviscosity (eg, epistaxis, bleeding gums, visual changes, headache, dizziness). Funduscopic examination should be performed in all patients with symptoms of hyperviscosity and/or IgM ≥3 g/dL (≥30 g/L). (See
         <a class="medical medical_review" href="/z/d/html/6657.html" rel="external">
          "Epidemiology, pathogenesis, clinical manifestations, and diagnosis of Waldenström macroglobulinemia", section on 'Hyperviscosity syndrome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of infections and systemic symptoms including fever, weight loss, drenching night sweats, and fatigue. Presence of lymphadenopathy, hepatosplenomegaly, and/or pleural effusions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Peripheral neuropathy, which may be related to myelin-associated glycoprotein antibody-positive demyelinating peripheral neuropathy. (See
         <a class="medical medical_review" href="/z/d/html/5264.html" rel="external">
          "Chronic inflammatory demyelinating polyneuropathy: Etiology, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical manifestations of:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cryoglobulinemia (eg, purpura, digital ischemia, arthralgia, fever, Raynaud phenomenon). (See
         <a class="medical medical_review" href="/z/d/html/1825.html" rel="external">
          "Overview of cryoglobulins and cryoglobulinemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cold agglutinin disease (eg, livido reticularis, acrocyanosis, Raynaud phenomenon). (See
         <a class="medical medical_review" href="/z/d/html/7084.html" rel="external">
          "Cold agglutinin disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Immunoglobulin light chain (AL) amyloidosis (eg, nephrotic syndrome, axonal neuropathy, unexplained cardiac failure, intestinal dysmotility, purpura, macroglossia). (See
         <a class="medical medical_review" href="/z/d/html/6668.html" rel="external">
          "Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Central nervous system (CNS) involvement (ie, Bing Neel syndrome), including headache, seizure, altered mental status, cranial nerve palsy, limb weakness, and/or atypical neuropathy. (See
         <a class="medical medical_review" href="/z/d/html/6657.html" rel="external">
          "Epidemiology, pathogenesis, clinical manifestations, and diagnosis of Waldenström macroglobulinemia", section on 'Neuropathy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         It is our practice to perform the following pretreatment studies in patients with WM:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Standard laboratory studies include a complete blood count with differential, chemistries with liver and kidney function and electrolytes, lactate dehydrogenase, serum protein electrophoresis, quantitative immunoglobulins and immunofixation, beta-2 microglobulin, and serum free light chain assay.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We also obtain the following tests in a subset of patients:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Serum viscosity in those with suspected hyperviscosity syndrome.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Coombs test in those with suspected cold agglutinin disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prothrombin time (PT), activated partial thromboplastin time (aPTT), and screening for von Willebrand disease (ie, von Willebrand factor [VWF] antigen, VWF activity, and factor VIII activity) in patients with abnormal bruising and/or bleeding, especially mucocutaneous bleeding.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hepatitis C serology in patients with cryoglobulinemia and prior to treatment in all patients. (See
         <a class="medical medical_review" href="/z/d/html/3676.html" rel="external">
          "Extrahepatic manifestations of hepatitis C virus infection", section on 'Essential mixed cryoglobulinemia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hepatitis B and human immunodeficiency virus (HIV) serology prior to treatment in all patients. (See
         <a class="medical medical_review" href="/z/d/html/3649.html" rel="external">
          "Hepatitis B virus reactivation associated with immunosuppressive therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unilateral bone marrow aspiration and biopsy for pathologic review, including immunophenotyping and
         <em>
          MYD88
         </em>
         mutation analysis plus
         <em>
          CXCR4
         </em>
         mutation, if possible. (See
         <a class="local">
          'Bruton tyrosine kinase inhibitors'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Computed tomography (CT) of the chest, abdomen, and pelvis with intravenous contrast to measure lymphadenopathy and extramedullary involvement. Integrated whole-body positron emission tomography (PET) with CT in cases suspected to have a more aggressive histology. We have a low threshold to biopsy areas with intense fluorodeoxyglucose (FDG) avidity (eg, standardized uptake value [SUV] &gt;10). (See
         <a class="medical medical_review" href="/z/d/html/4696.html" rel="external">
          "Pretreatment evaluation and staging of non-Hodgkin lymphomas", section on 'Imaging'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evaluation of patients with peripheral neuropathy also includes (see
         <a class="medical medical_review" href="/z/d/html/6657.html" rel="external">
          "Epidemiology, pathogenesis, clinical manifestations, and diagnosis of Waldenström macroglobulinemia", section on 'Neuropathy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14174.html" rel="external">
          "Immune-mediated neuropathies", section on 'Waldenström macroglobulinemia'
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Serologic testing for anti-myelin-associated glycoprotein, anti-ganglioside M1, and anti-sulfatide IgM antibodies
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Electromyography (EMG)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Evaluation for amyloid deposition
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Evaluation to exclude other causes of neuropathy, such as diabetes, vitamin B12 deficiency, thyroid dysfunction, and Lyme disease
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evaluation of patients with symptoms suggestive of infiltration of the CNS (ie, Bing Neel syndrome) also includes a magnetic resonance imaging (MRI) of the CNS and an assessment of the cerebral spinal fluid (cytology, flow cytometry, and molecular studies) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with childbearing potential should receive counseling about the potential effect of treatment on their fertility and options for fertility-preserving measures. (See
         <a class="medical medical_review" href="/z/d/html/7440.html" rel="external">
          "Fertility and reproductive hormone preservation: Overview of care prior to gonadotoxic therapy or surgery"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7455.html" rel="external">
          "Effects of cytotoxic agents on gonadal function in adult men"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          INDICATIONS FOR TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Asymptomatic patients
         </span>
        </p>
        <p class="headingAnchor" id="H1830172681">
         <span class="h3">
          Observation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately one-quarter of patients with WM have no constitutional symptoms or anemia and no symptoms attributable to the IgM monoclonal protein or tumor infiltration at the time of presentation [
         <a href="#rid2">
          2
         </a>
         ]. These patients are considered to have smoldering WM and should not be treated until symptoms develop [
         <a href="#rid3">
          3
         </a>
         ]. The decision to postpone treatment in this population is based on their good prognosis without therapy and concerns over the short- and long-term complications of treatment.
        </p>
        <p>
         We follow asymptomatic patients with complete blood counts and monoclonal protein levels every four to six months for the first five years and then annually, if stable. Another reasonable option included in the National Comprehensive Cancer Network (NCCN) guidelines is to adjust monitoring based on the risk of progression as assessed by the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.awmrisk.com%2F&amp;token=j%2BtF41plvYHq0KcVLVNCgvRy%2F7qMBbNZx%2F92GO88k%2FGvALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=6654" target="_blank">
          asymptomatic WM patient risk calculator
         </a>
         with follow-up every 12 months for low risk, every 6 months for intermediate risk, and every 3 months for high risk [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Those who develop symptomatic disease, anemia, or thrombocytopenia are offered therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If disease progression is unclear, repeating evaluation three to six months later can help to clarify the disease tempo and whether treatment is indicated.
        </p>
        <p>
        </p>
        <p>
         While the severity of anemia and/or thrombocytopenia that merits treatment is not well-defined, we generally use a threshold of hemoglobin &lt;10 g/dL and platelet count &lt;100,000/microL.
        </p>
        <p>
         Studies that have used varying hemoglobin values (&lt;10 g/dL to &lt;12 g/dL) to implement treatment have all noted that smoldering WM may remain stable without treatment for long periods of time [
         <a href="#rid3">
          3,5-9
         </a>
         ]. Overall survival approximates that of the normal population, and the 10-year survival rate is 70 to 75 percent [
         <a href="#rid10">
          10,11
         </a>
         ].
        </p>
        <p>
         WM is not curable, and there is no evidence that the treatment of asymptomatic patients provides a survival benefit when compared with treatment at the time symptoms develop. Treatment is also associated with both short- and long-term complications that can decrease quality of life and potentially affect survival. As an example,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         administration can result in a clinically important temporary increase in serum IgM levels (IgM flare), prolonged immunosuppression, and the reactivation of a latent hepatitis B virus infection. As another example, a small percentage of patients treated with nucleoside analogs or alkylating agents develop a more aggressive lymphoma or leukemia [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2800247754">
         <span class="h3">
          Risk of progression
         </span>
         <span class="headingEndMark">
          —
         </span>
         The risk of progression to symptomatic disease is greater in the first five years after diagnosis with an estimated annual rate of progression in case series ranging from 4 to 15 percent [
         <a href="#rid3">
          3,5,7,13
         </a>
         ].
        </p>
        <p>
         The
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.awmrisk.com%2F&amp;token=i8%2Ft7v3%2F%2BQTlugHc9AllJ6FTVufrqkORSvXF2bmgsL4%3D&amp;TOPIC_ID=6654" target="_blank">
          asymptomatic WM patient risk calculator
         </a>
         can assess risk of progression using IgM level, bone marrow lymphoplasmacytic infiltration, beta-2 microglobulin, and albumin as continuous variables to stratify patients into three risk groups with different median time to progression (TTP):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High risk (median TTP 1.8 years)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intermediate risk (median TTP 4.8 years)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low risk (median TTP 9.3 years)
        </p>
        <p>
        </p>
        <p>
         This model was developed based on a retrospective cohort study that identified progression to symptomatic WM in 317 of 439 patients (72 percent) with smoldering WM followed for a median of 7.8 years and validated in two independent cohorts [
         <a href="#rid13">
          13
         </a>
         ]. Symptoms at progression included anemia (67 percent), neuropathy (20 percent), hyperviscosity (15 percent), and organomegaly (10 percent). The following variables were identified as independent predictors for progression:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         IgM ≥4500 mg/dL
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bone marrow lymphoplasmacytic infiltration ≥70 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beta-2 microglobulin ≥4 mg/dL
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Albumin ≤3.5 g/dL
        </p>
        <p>
        </p>
        <p>
         Analysis of a combined cohort also identified wild-type
         <em>
          MYD88
         </em>
         as an
         <em>
         </em>
         independent risk factor for progression.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Symptomatic patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment is indicated for patients with symptomatic WM as indicated by any of the following if attributable to the WM  (
         <a class="graphic graphic_table graphicRef97667" href="/z/d/graphic/97667.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef97649" href="/z/d/graphic/97649.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Systemic symptoms – Systemic symptoms – Recurrent fever, drenching night sweats, fatigue, and/or unintentional weight loss
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cytopenias – Hemoglobin ≤10 g/dL or platelet count &lt;100,000/microL; cold agglutinin anemia, immune hemolytic anemia and/or thrombocytopenia
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Physical signs or symptoms of infiltration – Symptomatic or bulky (≥5 cm) lymphadenopathy, symptomatic hepatomegaly, symptomatic splenomegaly, and/or tissue infiltration
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         End organ damage – Hyperviscosity, peripheral neuropathy, immunoglobulin light chain (AL) amyloidosis with organ dysfunction, symptomatic cryoglobulinemia, pleural effusions, or nephropathy due to WM
        </p>
        <p>
        </p>
        <p>
         Symptomatic hyperviscosity is a
         <strong>
          medical emergency
         </strong>
         that requires prompt plasmapheresis. Signs and symptoms concerning for hyperviscosity include oronasal bleeding, blurred vision, headache, dizziness, paresthesias, retinal vein engorgement and flame-shaped hemorrhages, papilledema, stupor, and coma. (See
         <a class="local">
          'Emergency management of hyperviscosity'
         </a>
         below.)
        </p>
        <p>
         Management of WM-associated peripheral neuropathy requires coordination between clinicians with expertise in hematology and neurology [
         <a href="#rid14">
          14
         </a>
         ]. Treatment of the underlying WM can ameliorate the peripheral neuropathy, but complete resolution is uncommon. Care should be taken to limit exposure to potentially neurotoxic agents and minimize the risk of IgM flare. (See
         <a class="medical medical_review" href="/z/d/html/6657.html" rel="external">
          "Epidemiology, pathogenesis, clinical manifestations, and diagnosis of Waldenström macroglobulinemia", section on 'Neuropathy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          INITIAL TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Experts differ in their approach to the treatment of WM. While various drugs and combinations have demonstrated clinical benefit in prospective trials, few have been compared directly in randomized trials. In addition, individual trials have used different response criteria, thereby making it difficult to compare these agents or regimens based on response rates alone.
        </p>
        <p>
         Our approach is generally consistent with the consensus treatment recommendations proposed by the International Workshops on WM (IWWM-11), Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART), British Society for Haematology, and National Comprehensive Cancer Network (NCCN)  (
         <a class="graphic graphic_algorithm graphicRef97649" href="/z/d/graphic/97649.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid15">
          15-19
         </a>
         ]. There are limited data comparing different treatment approaches, and other experts advocate for the earlier incorporation of novel agents (eg, Bruton tyrosine kinase inhibitors) for a larger percentage of patients [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H28253348">
         <span class="h2">
          General treatment principles
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial management of patients with symptomatic WM is dependent on age, the severity of symptoms, presence of comorbidities, and patient preferences  (
         <a class="graphic graphic_algorithm graphicRef97649" href="/z/d/graphic/97649.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
         When choosing a therapy, the following principles apply:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         WM cannot be cured with current therapies. Instead, the goals of treatment are to control symptoms and prevent end-organ damage while maximizing quality of life.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Therapy is reserved for patients with symptomatic disease since asymptomatic patients may do well without therapy, and treatment has potential short- and long-term complications. (See
         <a class="local">
          'Asymptomatic patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with symptoms of hyperviscosity require emergency plasmapheresis in addition to therapy directed at the malignant clone. (See
         <a class="local">
          'Emergency management of hyperviscosity'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The intensity of the regimen is dictated by the severity of symptoms; patients with highly symptomatic disease are offered more intense regimens (eg,
         <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">
          bendamustine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         ; or
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         ,
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         , and rituximab) that may have a quicker response time but increased side effects, while patients with minimal symptoms may be offered regimens (eg, dexamethasone, rituximab, and
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ) that are better tolerated but slower. (See
         <a class="local">
          'Choice of initial therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The treatment regimens vary by delivery route and length of therapy. Rituximab-based and bortezomib-based regimens are administered parenterally over a defined period of time. BTK inhibitors are oral medications administered daily until progression.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          Rituximab
         </a>
         is frequently associated with a transient increase in serum IgM level (IgM flare) after administration, which can result in symptoms of hyperviscosity or worsen symptoms of neuropathy, cold agglutinin disease, or cryoglobulinemia. Treatment modifications can reduce the risk of IgM flare. (See
         <a class="local">
          'Minimizing risk of IgM flare with rituximab'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Emergency management of hyperviscosity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Symptomatic hyperviscosity is a
         <strong>
          medical emergency
         </strong>
         that requires prompt plasmapheresis. Red blood cell transfusions should be avoided, if possible, prior to plasmapheresis since they might further increase serum viscosity. Although the diagnosis is established by measuring serum viscosity, the clinician should make the decision to initiate plasmapheresis based on the patient's symptoms and physical findings (eg, oronasal bleeding, blurred vision, headaches, dizziness, paresthesias, retinal vein engorgement and flame-shaped hemorrhages, papilledema, stupor and coma) rather than on the magnitude of the viscosity measurement. (See
         <a class="medical medical_review" href="/z/d/html/6657.html" rel="external">
          "Epidemiology, pathogenesis, clinical manifestations, and diagnosis of Waldenström macroglobulinemia", section on 'Hyperviscosity syndrome'
         </a>
         .)
        </p>
        <p>
         The only effective treatment for the hyperviscosity syndrome is the removal of IgM from the circulation via plasmapheresis. The large size of the IgM molecule restricts it mainly to the intravascular space such that it can be rapidly removed with plasmapheresis, resulting in prompt alleviation of symptoms. Details of the plasmapheresis procedure are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7941.html" rel="external">
          "Therapeutic apheresis (plasma exchange or cytapheresis): Indications and technology"
         </a>
         .)
        </p>
        <p>
         The following general principles regarding plasmapheresis for hyperviscosity syndrome are important:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients presenting with severe neurologic impairment, such as stupor or coma in the absence of subdural or intracranial bleeding, should be treated with plasmapheresis on an
         <strong>
          emergency
         </strong>
         basis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptoms should subside with the lowering of serum viscosity. However, irreversible changes can occur, such as those due to venous thrombosis in the central nervous system and other sites.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Plasmapheresis does not affect the disease process. In most cases, serum IgM levels will rise, and symptoms of hyperviscosity will recur within a few weeks of stopping plasmapheresis unless therapy directed at the malignant cells is initiated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A reasonable initial prescription is a total plasma volume exchange (ie, 3 to 4 liters in an adult) replaced with albumin (rather than plasma), repeated daily until symptoms subside or until serum viscosity is normal.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyperviscosity syndromes are usually associated with an increased plasma volume. Thus, the volume of plasma needed for a "one volume exchange" may be greater than that calculated by commonly used formulae.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Transfusion with packed red blood cells during this period may further increase whole blood viscosity and precipitate or aggravate heart failure.
        </p>
        <p>
        </p>
        <p>
         Our approach is consistent with the 2023 guidelines published by the American Society for Apheresis [
         <a href="#rid21">
          21
         </a>
         ] and the 2023 consensus treatment recommendations proposed by the IWWM-11 [
         <a href="#rid15">
          15,19
         </a>
         ], which conclude that plasmapheresis is first-line therapy for hyperviscosity syndrome and may be used before
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         administration to prevent flare in patients with high IgM levels (typically &gt;4000 mg/dL).
        </p>
        <p>
         This recommendation is supported by low-quality evidence from small observational studies demonstrating efficacy of plasmapheresis in this setting and large observational studies demonstrating the safety of plasmapheresis in general. There have been no randomized trials of plasmapheresis in the management of hyperviscosity syndrome.
        </p>
        <p>
         The published literature consists of prospective trials with historical controls, case series, and case reports accumulating data on approximately 300 patients [
         <a href="#rid22">
          22
         </a>
         ]. These studies have demonstrated that a single plasmapheresis treatment reduces IgM levels by 30 to 50 percent and is associated with a decrease in serum viscosity, an increase in capillary blood flow, and an improvement in the clinical manifestations of hyperviscosity [
         <a href="#rid21">
          21,23-29
         </a>
         ]. Complications due to plasmapheresis are seen in less than 2 percent of patients replaced with albumin and most commonly consist of citrate-induced paresthesias, muscle cramps, and urticaria. The complications of plasmapheresis are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7942.html" rel="external">
          "Therapeutic apheresis (plasma exchange or cytapheresis): Complications"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2964681176">
         <span class="h2">
          Minimizing risk of IgM flare with rituximab
         </span>
         <span class="headingEndMark">
          —
         </span>
         The addition of an anti-CD20 monoclonal antibody (eg,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         ,
         <a class="drug drug_general" data-topicid="9523" href="/z/d/drug information/9523.html" rel="external">
          ofatumumab
         </a>
         ) to combination chemotherapy improves response rates and prolongs remissions, but it is also associated with a transient, yet clinically important increase in serum IgM levels (IgM flare) and viscosity [
         <a href="#rid30">
          30
         </a>
         ]. Clinical and laboratory monitoring is therefore warranted in patients receiving an anti-CD20 monoclonal antibody for WM during the first one to two cycles.
        </p>
        <p>
         We agree with the 2023 guidelines published by the American Society for Apheresis [
         <a href="#rid21">
          21
         </a>
         ] and the 2023 consensus treatment recommendations proposed by the IWWM-11 [
         <a href="#rid15">
          15,19
         </a>
         ], which conclude that plasmapheresis is first-line therapy for hyperviscosity syndrome and may be used before anti-CD20 monoclonal antibody administration to prevent flare in patients with high IgM levels (typically &gt;4000 mg/dL). Alternatively, the anti-CD20 monoclonal antibody may be withheld for the first cycle in patients with high IgM levels receiving combination therapy.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          CHOICE OF INITIAL THERAPY
         </span>
        </p>
        <p class="headingAnchor" id="H865114398">
         <span class="h2">
          Choice of initial therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most patients with treatment-naïve, symptomatic WM, we prefer
         <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">
          bendamustine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         (BR) rather than other chemotherapy regimens or a Bruton tyrosine kinase (BTK) inhibitor, as BR is an effective option that can be given over a short, defined course (four to six months) with an acceptable toxicity profile  (
         <a class="graphic graphic_algorithm graphicRef97649" href="/z/d/graphic/97649.html" rel="external">
          algorithm 1
         </a>
         ). Continuous therapy with a BTK inhibitor is an appropriate alternative for older adults and for others who are not eligible for or do not want systemic chemotherapy.
        </p>
        <p>
         While they have demonstrated activity in WM, treatment burdens differ, and most of these treatment options have not been directly compared with each other in prospective trials. In addition, it is difficult to compare these agents based on response rates alone since individual trials have used different response criteria.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bendamustine plus rituximab – We prefer BR as the initial therapy for most patients [
         <a href="#rid31">
          31-34
         </a>
         ]; the vast majority will have at least a partial response with this approach. BR is a moderately intensive, time-limited therapy administered monthly over a period of four to six months, followed by a treatment-free period. It consists of intravenous
         <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">
          bendamustine
         </a>
         (dose: 90 mg/m
         <sup>
          2
         </sup>
         given over 30 to 60 minutes on days 1 and 2 of each cycle) in combination with
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         (dose: 375 mg/m
         <sup>
          2
         </sup>
         on day 1 of each cycle) [
         <a href="#rid31">
          31
         </a>
         ]. Lower doses of bendamustine are used for older patients and those with kidney impairment. The most common toxicities are myelosuppression, hypogammaglobulinemia, and infection. Other toxicities include an increased risk of secondary myeloid neoplasms. (See
         <a class="local">
          'Bendamustine plus rituximab'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) – A BTK inhibitor is an appropriate alternative for older patients and for others who are not eligible for or do not want systemic chemotherapy. BTK inhibitors are highly effective oral medications given until disease progression or unacceptable toxicity. While toxicity is greatest in the first six months of treatment, it continues for the duration of therapy. Important toxicities include bleeding, atrial fibrillation, and hypertension. Other toxicities include fatigue, rash, infections, and myalgia/arthralgia. (See
         <a class="local">
          'Bruton tyrosine kinase inhibitors'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dexamethasone, rituximab, cyclophosphamide (DRC) – DRC is an acceptable alternative to BR if disease burden is low. This regimen consists of intravenous
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         (dose: 20 mg on day 1) followed by intravenous
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         (dose: 375 mg/m
         <sup>
          2
         </sup>
         on day 1) in addition to oral
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         (dose: 100 mg/m
         <sup>
          2
         </sup>
         twice daily on days 1 to 5) [
         <a href="#rid35">
          35
         </a>
         ]. This regimen is repeated every 21 days for a total of six courses. (See
         <a class="local">
          'Dexamethasone, rituximab, and cyclophosphamide'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bortezomib plus rituximab with or without dexamethasone (BDR) – We usually reserve BDR for relapsed WM. While it has demonstrated efficacy, there is an increased risk of neurotoxicity. This regimen usually consists of weekly
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         combined with
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         at various schedules with or without
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         [
         <a href="#rid36">
          36-40
         </a>
         ]. Subcutaneous administration of bortezomib helps to reduce neuropathy. (See
         <a class="local">
          'Bortezomib, dexamethasone, and rituximab'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1937557174">
         <span class="h2">
          Bendamustine plus rituximab
         </span>
         <span class="headingEndMark">
          —
         </span>
         BR is our preferred regimen for most patients with high tumor burden or moderate/severe symptoms  (
         <a class="graphic graphic_algorithm graphicRef97649" href="/z/d/graphic/97649.html" rel="external">
          algorithm 1
         </a>
         ). BR offers effective, time-limited therapy.
        </p>
        <p>
         BR consists of intravenous
         <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">
          bendamustine
         </a>
         (dose: 90 mg/m
         <sup>
          2
         </sup>
         given over 30 to 60 minutes on days 1 and 2 of each cycle) in combination with
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         (dose: 375 mg/m
         <sup>
          2
         </sup>
         on day 1 of each cycle) [
         <a href="#rid31">
          31
         </a>
         ]. This regimen is repeated every four weeks for four to six cycles. Lower doses of bendamustine are used for older patients and those with kidney impairment.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          Rituximab
         </a>
         is also associated with a transient, yet clinically important increase in serum IgM levels (IgM flare) and viscosity [
         <a href="#rid30">
          30
         </a>
         ]. All patients should be monitored for IgM flare. Those with IgM &gt;4000 mg/dL also receive interventions to decrease this risk (either prophylactic plasmapheresis or withholding rituximab). (See
         <a class="local">
          'Minimizing risk of IgM flare with rituximab'
         </a>
         above.)
        </p>
        <p>
         Support for the use of BR in WM comes from prospective trials, which have demonstrated overall response rates over 90 percent and relatively good tolerability:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A phase 2 trial of BR in 63 patients with low-grade lymphoma included 17 patients with lymphoplasmacytic lymphoma [
         <a href="#rid31">
          31
         </a>
         ]. Overall and complete response (CR) rates were 90 and 60 percent, respectively. The most common toxicity was myelosuppression with severe (grade 3 or 4) leukopenia and thrombocytopenia in 16 and 3 percent, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The phase 3 Study Group Indolent Lymphomas (StiL) trial compared BR versus R-CHOP (
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         ,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         ) in patients with indolent lymphoma [
         <a href="#rid32">
          32
         </a>
         ]. A subset analysis of the 41 patients with WM found that, when compared with R-CHOP, BR was better tolerated (eg, lower rates of infections, cytopenias, neuropathy, stomatitis, and alopecia), resulted in a similar overall response rate (approximately 95 percent), and improved median progression-free survival (PFS; 70 versus 28 months).
        </p>
        <p>
        </p>
        <p>
         Similar response rates and PFS were reported in a larger multicenter retrospective study of BR in WM [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         The most common toxicities are myelosuppression, hypogammaglobulinemia, and infection.
         <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">
          Bendamustine
         </a>
         induces dose-dependent deoxyribonucleic acid (DNA) damage and a risk of secondary myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), although an increased incidence of MDS/AML after bendamustine has not been clearly demonstrated [
         <a href="#rid42">
          42
         </a>
         ]. General side effects of
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         include infusion reactions, increased risk of infection, and impaired vaccination responses. Rituximab therapy is also associated with the risk of hepatitis B virus (HBV) reactivation among patients positive for HBV surface antigen (HBsAg) or HBV core antibody (anti-HBc). (See
         <a class="medical medical_review" href="/z/d/html/3649.html" rel="external">
          "Hepatitis B virus reactivation associated with immunosuppressive therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7501.html" rel="external">
          "Rituximab: Principles of use and adverse effects in rheumatoid arthritis"
         </a>
         .)
        </p>
        <p>
         After the completion of four to six cycles of BR, we offer observation with treatment at the time of progression rather than the use of maintenance therapy. While maintenance
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         has prolonged remission in some other indolent forms of non-Hodgkin lymphoma, a PFS benefit has not been clearly demonstrated in WM, and there is no improvement in overall survival with maintenance [
         <a href="#rid43">
          43
         </a>
         ]. Instead, treatment is given to alleviate the signs or symptoms that prompted treatment initiation. Once there is improvement in these parameters, there is no clear benefit to continued therapy. Maintenance therapy has associated side effects, inconvenience, and cost and has not demonstrated a clinical benefit.
        </p>
        <p class="headingAnchor" id="H1836957764">
         <span class="h2">
          Bruton tyrosine kinase inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         A BTK inhibitor (
         <a class="drug drug_general" data-topicid="126183" href="/z/d/drug information/126183.html" rel="external">
          zanubrutinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          ibrutinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="115440" href="/z/d/drug information/115440.html" rel="external">
          acalabrutinib
         </a>
         ) is an appropriate initial therapy for older patients and for others who are not eligible for or do not want systemic chemotherapy. Prospective studies have demonstrated high response rates and sustained remissions with this approach. However, there have been no randomized trials comparing the efficacy and tolerability of BTK inhibitors versus other treatment regimens in WM. While other experts advocate for initial therapy with a BTK inhibitor in most patients [
         <a href="#rid20">
          20
         </a>
         ], we prefer time-limited therapy with BR for eligible patients and reserve BTK inhibitors for the treatment of relapsed or refractory WM.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          Ibrutinib
         </a>
         and
         <a class="drug drug_general" data-topicid="126183" href="/z/d/drug information/126183.html" rel="external">
          zanubrutinib
         </a>
         are both approved by the US Food and Drug Administration (FDA) for the treatment of WM. While we have longer follow-up with ibrutinib, zanubrutinib appears to be more effective and better tolerated [
         <a href="#rid44">
          44,45
         </a>
         ].
         <a class="drug drug_general" data-topicid="115440" href="/z/d/drug information/115440.html" rel="external">
          Acalabrutinib
         </a>
         does not have regulatory approval in this setting.
        </p>
        <p class="headingAnchor" id="H2479956572">
         <span class="h3">
          Zanubrutinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="126183" href="/z/d/drug information/126183.html" rel="external">
          Zanubrutinib
         </a>
         is our preferred option for older patients and for others who are not eligible for or do not want systemic chemotherapy. It is a highly effective, oral therapy for WM. When compared with
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          ibrutinib
         </a>
         , zanubrutinib appears to be more effective and better tolerated [
         <a href="#rid44">
          44,45
         </a>
         ]. Zanubrutinib is also effective and well-tolerated in patients intolerant of ibrutinib or
         <a class="drug drug_general" data-topicid="115440" href="/z/d/drug information/115440.html" rel="external">
          acalabrutinib
         </a>
         [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="126183" href="/z/d/drug information/126183.html" rel="external">
          Zanubrutinib
         </a>
         is administered by mouth at a dose of 160 mg twice daily or 320 mg once daily until disease progression or unacceptable toxicity [
         <a href="#rid47">
          47
         </a>
         ]. Prescribing information highlights the need to monitor for bleeding, infections, cytopenias, and cardiac arrhythmias. Consider holding zanubrutinib for three to seven days before and after surgery to mitigate the risk of perioperative bleeding. Patients have developed second primary malignancies, including skin cancers, and patients are advised to use sun protection.
        </p>
        <p>
         Support for
         <a class="drug drug_general" data-topicid="126183" href="/z/d/drug information/126183.html" rel="external">
          zanubrutinib
         </a>
         comes from a multicenter phase 3 trial (ASPEN), in which 201 patients with
         <em>
          MYD88
         </em>
         mutated WM were randomly assigned to zanubrutinib or
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          ibrutinib
         </a>
         , each given until disease progression or unacceptable toxicity [
         <a href="#rid44">
          44,45
         </a>
         ]. After a median follow-up of 44.4 months, zanubrutinib resulted in:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Faster and deeper responses, with the best responses seen in those with
         <em>
          MYD88
         </em>
         mutated,
         <em>
          CXCR4
         </em>
         wild-type WM.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Similar PFS and overall survival (OS; 42-month PFS 78 versus 70 percent; hazard ratio [HR] 0.63, 95% CI 0.36 to 1.12; 42-month OS 88 versus 85 percent; HR 0.75, 95% CI 0.36 to 1.59).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Less toxic, requiring fewer dose reductions and fewer discontinuations due to toxicity (9 versus 20 percent) with lower rates of diarrhea, muscle spasms, hypertension, atrial fibrillation/atrial flutter, and pneumonia; while there was a higher rate of neutropenia, infection rates were similar, and the prevalence of neutropenia and infection decreased over time.
        </p>
        <p>
        </p>
        <p>
         The ASPEN trial also reported outcomes with
         <a class="drug drug_general" data-topicid="126183" href="/z/d/drug information/126183.html" rel="external">
          zanubrutinib
         </a>
         in 26 patients with
         <em>
          MYD88
         </em>
         wild-type WM [
         <a href="#rid45">
          45,48
         </a>
         ]. There was one CR, and the rate of very good partial response (VGPR) plus CR was 30.8 percent. Estimated PFS and OS at 42 months were 54 and 84 percent, respectively.
        </p>
        <p>
         In addition, a single-arm trial evaluated two dosing schedules of
         <a class="drug drug_general" data-topicid="126183" href="/z/d/drug information/126183.html" rel="external">
          zanubrutinib
         </a>
         in patients with treatment-naïve (24 patients) or relapsed/refractory (53 patients) WM [
         <a href="#rid49">
          49
         </a>
         ]. Rates of CR plus VGPR increased with time and were 44 percent at 24 months. At a median follow-up of 36 months, the estimated rates of PFS and OS at three years were 81 and 85 percent, respectively.
        </p>
        <p class="headingAnchor" id="H3106909473">
         <span class="h3">
          Ibrutinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          Ibrutinib
         </a>
         is an option for older patients and for others who are not eligible for or do not want systemic chemotherapy. It is a highly effective, oral therapy for WM, although
         <a class="drug drug_general" data-topicid="126183" href="/z/d/drug information/126183.html" rel="external">
          zanubrutinib
         </a>
         may be preferred based on its better tolerability and likely greater efficacy [
         <a href="#rid44">
          44,45
         </a>
         ]. Some but not all data suggest that ibrutinib is less effective in WM with
         <em>
          CXCR4
         </em>
         mutations [
         <a href="#rid50">
          50-53
         </a>
         ].
        </p>
        <p>
         While prospective trials have evaluated the use of
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          ibrutinib
         </a>
         as a single agent and in combination with
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , none has compared these two approaches. As there is no clear benefit to the addition of rituximab, we usually offer single-agent ibrutinib.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          Ibrutinib
         </a>
         is administered at a dose of 420 mg by mouth daily until disease progression or unacceptable toxicity [
         <a href="#rid54">
          54
         </a>
         ]. If included,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         (dose: 375 mg/m
         <sup>
          2
         </sup>
         ) is administered once per week on weeks 1 through 4 and 17 through 20 [
         <a href="#rid55">
          55
         </a>
         ]. While generally well-tolerated, uncommon toxicities, including bleeding, infection, atrial fibrillation, ventricular arrhythmias, and hypertension, are seen [
         <a href="#rid54">
          54,56-58
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          Ibrutinib
         </a>
         is generally avoided in patients with a history of arrhythmia, significant hepatic impairment, or severe bleeding and in those on anticoagulation, although some of these (eg, atrial fibrillation, anticoagulation) may become less of a concern as experience with ibrutinib increases. Consider holding ibrutinib for three to seven days before and after surgery to mitigate the risk of perioperative bleeding. Case reports have described withdrawal symptoms and IgM flare in some patients following temporary or permanent discontinuation [
         <a href="#rid58">
          58-60
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4520.html" rel="external">
          "Treatment of relapsed or refractory chronic lymphocytic leukemia", section on 'Ibrutinib'
         </a>
         .)
        </p>
        <p>
         Data regarding the use of
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          ibrutinib
         </a>
         in WM come from randomized trials comparing it with
         <a class="drug drug_general" data-topicid="126183" href="/z/d/drug information/126183.html" rel="external">
          zanubrutinib
         </a>
         or placebo and single-arm trials with longer follow-up. It has not been directly compared with time-limited therapy with BR.
        </p>
        <p>
         As described separately, in the randomized ASPEN trial,
         <a class="drug drug_general" data-topicid="126183" href="/z/d/drug information/126183.html" rel="external">
          zanubrutinib
         </a>
         had improved tolerability and similar efficacy when compared with
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          ibrutinib
         </a>
         (42-month PFS 78 versus 70 percent; HR 0.63, 95% CI 0.36 to 1.12; 42-month OS 88 versus 85 percent; HR 0.75, 95% CI 0.36 to 1.59) [
         <a href="#rid44">
          44,45
         </a>
         ]. (See
         <a class="local">
          'Zanubrutinib'
         </a>
         above.)
        </p>
        <p>
         The combination of
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          ibrutinib
         </a>
         plus
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         was compared with placebo plus rituximab in a randomized trial (iNNOVATE) that enrolled 150 patients with symptomatic WM, 68 of whom had not received prior therapy [
         <a href="#rid53">
          53,55
         </a>
         ]. The addition of ibrutinib to rituximab resulted in higher rates of major response (72 versus 32 percent) and sustained improvement in hemoglobin (73 versus 41 percent), and improved PFS (54-month PFS 68 versus 25 percent; HR 0.25, 95% CI 0.15-0.42) regardless of
         <em>
          CXCR4
         </em>
         mutation status. Ibrutinib plus rituximab resulted in higher rates of atrial fibrillation (12 versus 1 percent) and hypertension (13 versus 4 percent) and lower rates of anemia (11 versus 17 percent), infusion reactions (1 versus 16 percent), and IgM flare (8 versus 47 percent). OS data are immature with &gt;50 percent of patients in both arms alive at 54 months (HR 0.81, 95% CI 0.33 to 1.99). These results demonstrate that the addition of ibrutinib to rituximab improves PFS and decreases the risk of IgM flare and associated complications. It is unknown how this combination compares with ibrutinib as a single agent or with other rituximab-based combination therapies.
        </p>
        <p>
         Three smaller, single-arm trials evaluated
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          ibrutinib
         </a>
         monotherapy in a total of 124 patients with symptomatic WM [
         <a href="#rid50">
          50,61-66
         </a>
         ]. The overall response rate was &gt;90 percent. There were no CRs. Responses appeared to be deeper among those with mutated
         <em>
          MYD88
         </em>
         and wild-type
         <em>
          CXCR4
         </em>
         . In one trial with a median follow-up of 59 months, estimated PFS at five years was 54 percent for the population as a whole and differed by mutation status (
         <em>
          MYD88
         </em>
         <sup>
          Mut
         </sup>
         <em>
          CXCR
         </em>
         <sup>
          WT
         </sup>
         70 percent;
         <em>
          MYD88
         </em>
         <sup>
          Mut
         </sup>
         <em>
          CXRC
         </em>
         <sup>
          Mut
         </sup>
         38 percent;
         <em>
          MYD88
         </em>
         <sup>
          WT
         </sup>
         <em>
          CXCR
         </em>
         <sup>
          WT
         </sup>
         0 percent) [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
         Similar response rates were reported in a multicenter retrospective study of
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          ibrutinib
         </a>
         in 28 patients with infiltration of the central nervous system (Bing-Neel syndrome) [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3072536426">
         <span class="h3">
          Acalabrutinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="115440" href="/z/d/drug information/115440.html" rel="external">
          Acalabrutinib
         </a>
         does not have regulatory approval for use in WM, although prospective trials have demonstrated efficacy and relatively good tolerability.
        </p>
        <p>
         In a multicenter phase 2 trial of 106 patients treated with
         <a class="drug drug_general" data-topicid="115440" href="/z/d/drug information/115440.html" rel="external">
          acalabrutinib
         </a>
         , the overall response rate was 93 percent (none complete) [
         <a href="#rid68">
          68
         </a>
         ]. After a median follow-up of 27 months, estimated 24-month PFS and OS rates were 90 and 92 percent, respectively. Thirty patients (28 percent) discontinued acalabrutinib during the study period. Adverse events were consistent with those seen in patients taking acalabrutinib for other conditions. The most common were headache, diarrhea, contusion, dizziness, fatigue, nausea, upper respiratory tract infection, and constipation. Serious adverse events occurred in approximately one-half of patients, and there was one treatment-related death secondary to intracranial hematoma.
        </p>
        <p class="headingAnchor" id="H4098187056">
         <span class="h2">
          Dexamethasone, rituximab, and cyclophosphamide
         </span>
         <span class="headingEndMark">
          —
         </span>
         If the disease burden is low, DRC is an acceptable alternative to BR and is associated with fewer toxicities. While the addition of
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         to DRC resulted in faster, deeper responses, it increases the risk of peripheral neuropathy [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
         DRC consists of intravenous
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         (dose: 20 mg on day 1) followed by intravenous
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         (dose: 375 mg/m
         <sup>
          2
         </sup>
         on day 1) in addition to oral
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         (dose: 100 mg/m
         <sup>
          2
         </sup>
         twice daily on days 1 to 5) [
         <a href="#rid35">
          35
         </a>
         ]. This regimen is repeated every 21 days for a total of six courses.
        </p>
        <p>
         A phase II trial investigated the use of DRC in 72 patients with previously untreated symptomatic WM [
         <a href="#rid35">
          35
         </a>
         ]. Overall response and CR rates were 83 and 7 percent, respectively, with two-year OS and PFS rates of 81 and 67 percent, respectively. Median time to response was 4.1 months. Toxicities were generally mild (grade 1/2) and included nausea, alopecia, and neutropenia. Chills, fever, and headache that occurred during
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         infusion were readily reversible after reduction of the infusion rate.
        </p>
        <p>
         Additional data come from a retrospective analysis of outcomes following DRC [
         <a href="#rid70">
          70
         </a>
         ]. Among the 50 patients with previously untreated WM, the overall response rate was 96 percent, and the median PFS was 34 months. Among the 50 patients with relapsed or refractory WM, the overall response rate was 87 percent, and the median PFS was 32 months. The response rate and duration of response were independent of MYD88 mutation status.
        </p>
        <p>
         The addition of
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         to DRC was evaluated in a randomized trial of 204 patients with previously untreated symptomatic WM [
         <a href="#rid69">
          69
         </a>
         ]. After a median follow-up of 27.5 months, the addition of bortezomib resulted in a modest improvement in time to response and depth of response and similar PFS (24-month PFS 81 versus 73 percent). Rates of grade 3 or 4 toxicities were similar (50 versus 49 percent). However, the trial excluded patients with grade 2 or greater neuropathy. Of the 99 patients without symptoms of neuropathy at the start of treatment, 18 developed neuropathy, and 13 required a dose reduction in bortezomib because of neuropathy.
        </p>
        <p class="headingAnchor" id="H80987946">
         <span class="h2">
          Limited role for single-agent rituximab
         </span>
         <span class="headingEndMark">
          —
         </span>
         Single-agent
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         should not be used routinely for WM, particularly if the IgM level is &gt;4000 mg/dL. It is less effective than other treatment options and frequently results in a transient increase in serum IgM levels (IgM flare) that may lead to complications of hyperviscosity. Instead, rituximab is combined with chemotherapy, such as
         <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">
          bendamustine
         </a>
         (which increases efficacy and decreases the risk of IgM flare), or a BTK inhibitor is used instead. A potential exception is that single-agent rituximab may be offered to highly selected patients with manifestations of WM limited to neuropathy alone or hemolysis alone.
        </p>
        <p>
         Single-agent
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         can achieve a partial response in approximately one-half of patients; CRs have not been reported [
         <a href="#rid55">
          55,71-75
         </a>
         ]. Median times to partial and best response are approximately 4 and 17 months, respectively. Studies have reported abrupt and clinically important increases in serum IgM levels and viscosity in approximately one-half of patients at a mean of four weeks (range: one to eight) following initiation of treatment with rituximab [
         <a href="#rid75">
          75,76
         </a>
         ]. Clinical and laboratory monitoring for IgM flare is warranted. Symptoms of hyperviscosity must be treated with emergency plasmapheresis. (See
         <a class="local">
          'Emergency management of hyperviscosity'
         </a>
         above.)
        </p>
        <p>
         A small proportion of WM patients can become intolerant to
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         [
         <a href="#rid77">
          77
         </a>
         ]. Rituximab intolerance was seen in 7 percent of WM patients exposed to rituximab. Rituximab intolerance can develop while getting rituximab alone or in combination. In these patients,
         <a class="drug drug_general" data-topicid="9523" href="/z/d/drug information/9523.html" rel="external">
          ofatumumab
         </a>
         has been used with good tolerability.
        </p>
        <p class="headingAnchor" id="H779381971">
         <span class="h1">
          FOLLOW-UP
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients should be evaluated periodically to determine the disease response to treatment and should be followed longitudinally for relapse.
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Assessing response to therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Response to therapy is determined using the International Working Group on Waldenström Macroglobulinemia's simplified uniform response criteria (ie, "IWWM-11 response criteria," previously referred to as "simplified IWWM-6 response criteria") [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p>
         For patients treated with
         <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">
          bendamustine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , we evaluate disease response before each treatment cycle. For those treated with a Bruton tyrosine kinase (BTK) inhibitor, we initially assess disease response before each cycle. Once it is confirmed that the disease is responding, these assessments can be done every few cycles.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         This evaluation always includes a history and physical examination to evaluate for signs and symptoms of progressive disease, serum protein electrophoresis (SPEP), and serum quantitative IgM level. The serum free light chain (sFLC) assay is not used for the routine monitoring of patients with WM, except for those with WM-associated immunoglobulin light chain (AL) amyloidosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evaluation to confirm a suspected complete response (CR) also includes serum immunofixation and bone marrow aspiration and biopsy. CT imaging to confirm the absence of extramedullary disease is included if extramedullary disease was present at baseline. While studies suggest that it may have prognostic value, we do not routinely obtain positron emission tomography/CT [
         <a href="#rid79">
          79
         </a>
         ]. CR no longer requires reconfirmation at six weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Disease progression should be considered in patients with signs of active disease. These include clinically significant anemia, thrombocytopenia, leukopenia, adenopathy, hepatomegaly, or splenomegaly, or an increase in symptoms attributable to WM, which may include unexplained recurrent fever, drenching night sweats, ≥10 percent body weight loss, hyperviscosity, neuropathy, symptomatic cryoglobulinemia, or amyloidosis. (See
         <a class="local">
          'Pretreatment evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         Data from this evaluation is used to determine disease response, as follows [
         <a href="#rid78">
          78
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complete response – Absence of monoclonal IgM protein by SPEP and immunofixation; normal serum IgM level; no histologic evidence of bone marrow involvement; resolution of any extramedullary disease, including complete resolution or decrease in size of lymph nodes (≤1.5 cm), decrease in the size of spleen (≤15 cm), and complete resolution of any other non-lymph node/non-splenic extramedullary masses related to WM consistent with revised response criteria for lymphoma.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Very good partial response – ≥90 percent reduction in serum IgM level from baseline or level within normal range.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Partial response – ≥50 percent and &lt;90 percent reduction in serum IgM level from baseline.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Minor response – ≥25 percent and &lt;50 percent reduction of serum IgM level from baseline.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stable disease – &lt;25 percent reduction to &lt;25 percent increase in serum IgM level from baseline.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Progressive disease – Requires demonstration of progressive disease (PD) using either IgM or imaging criteria. If IgM level and imaging show discordant findings (eg, IgM response with PD on imaging), then assessment is considered PD.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Demonstration by IgM: ≥25 percent increase in serum IgM level from lowest nadir (minimum increase of 500 mg/dL from nadir) confirmed on a second sequential measurement. If one measurement suggests PD and the subsequent measurement does not, the patient has not met PD criteria. PD requires two sequential measurements consistent with PD. Suspected IgM flare or IgM rebound related to therapy should not be considered PD.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Demonstration by imaging showing any of the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Any new lesion (&gt;1.5 cm in any axis)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Previously involved extramedullary disease sites with unequivocal evidence of enlargement by &gt;50 percent in any axis to &gt;1.5 cm from nadir measurements
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Any new lesion consistent with transformed disease
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         PD by imaging does not require reconfirmation by repeat imaging.
        </p>
        <p>
        </p>
        <p>
         The term "major response" is used to identify patients who qualify for a partial, very good partial, or complete response. Serum monoclonal IgM levels provide an easily accessible measure of disease status but can sometimes fluctuate independent of disease activity. As an example, IgM levels can increase transiently after treatment with
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         or
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         . As such, bone marrow biopsy should be considered in patients with a clinical picture that does not appear concordant with the serum monoclonal IgM level.
        </p>
        <p>
         Importantly, IgM values are dependent on the method of measurement used (eg, nephelometry, densitometry). As such, sequential response assessments for individual patients should be performed in the same laboratory using the same methodology.
        </p>
        <p>
         Patients who have stable or progressive disease are treated as refractory disease. Responses to some chemotherapy regimens may not be seen until after several cycles of therapy. As such, we do not usually switch therapies for stable disease unless there is no response after three or more cycles. (See
         <a class="local">
          'Treatment of relapsed or refractory disease'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H779381995">
         <span class="h2">
          Monitoring for progressive disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with WM are monitored for the development of PD. The frequency of these evaluations depends on initial therapy used (time-limited chemotherapy versus continuous BTK inhibitor) and the comfort of both the patient and clinician.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Following
         </strong>
         <strong>
          bendamustine
         </strong>
         <strong>
          plus
         </strong>
         <strong>
          rituximab
         </strong>
         – Following the completion of therapy, we repeat a staging evaluation to document the response to therapy. Our approach to patient surveillance is to schedule patient visits every three months for the first year and then every six months. At these visits, we perform a history and physical examination, complete blood count, and measurement of monoclonal protein in serum or urine. There is no role for routine imaging studies in the longitudinal follow-up of asymptomatic patients after response assessment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          During Bruton tyrosine kinase inhibitor therapy
         </strong>
         – For those receiving continuous therapy with a BTK inhibitor, we typically schedule visits monthly for the first two to three months to ensure a response and then every three to six months once the disease has stabilized and the patient is clearly benefiting from therapy.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H858126">
         <span class="h2">
          Histologic transformation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Relapsed or refractory disease must be distinguished from histologic transformation, which requires a different treatment approach. Histologic transformation of WM into a rapidly progressive, high-grade malignant lymphoma may occur after a typical low-grade course [
         <a href="#rid80">
          80,81
         </a>
         ]. The transformation is usually associated with a decrease in performance status, rapid development of lymphadenopathy, increase in serum lactate dehydrogenase levels, presence of abnormal metaphase cytogenetics of involved bone marrow or lymph nodes, and often a decrease in the serum IgM level.
        </p>
        <p>
         Histologic transformation can be suggested by changes on imaging studies but can only be confirmed by biopsy. As such, a biopsy should always be obtained to document histologic transformation before proceeding with therapy. Survival from the time of transformation is usually very short, and response to treatment has been short-lived. The approach is similar to that of histologic transformation of follicular lymphoma, which is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4724.html" rel="external">
          "Histologic transformation of follicular lymphoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          TREATMENT OF RELAPSED OR REFRACTORY DISEASE
         </span>
        </p>
        <p class="headingAnchor" id="H505173520">
         <span class="h2">
          First relapse
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment options for patients with relapsed or refractory disease depend on the initial therapy given and the timing of progression. In general, it is not necessary to restart therapy based on monoclonal protein elevations alone in patients who have previously achieved a major response to therapy; rather, the criteria for reinitiation of therapy are similar to those used in newly diagnosed patients and include recurrence of symptoms and cytopenias. Similarly, for patients treated with a BTK inhibitor, it is reasonable to continue therapy despite a rise in monoclonal protein levels as long as the patient is demonstrating a clinical benefit and the therapy is well-tolerated. Relapsed or refractory disease must be distinguished from histologic transformation, which requires a different treatment approach. (See
         <a class="local">
          'Histologic transformation'
         </a>
         above.)
        </p>
        <p>
         Experts differ in their approach to the management of relapsed or refractory disease, and there have been no randomized trials to guide therapy. The following approach is based on a review of the existing data, clinical experience, and observations [
         <a href="#rid82">
          82
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For symptomatic patients relapsing more than three years following initial systemic chemotherapy (eg,
         <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">
          bendamustine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         [BR]), we repeat the original treatment. With such an approach, patients may respond almost equally well as they did the first time. A Bruton tyrosine kinase (BTK) inhibitor is an acceptable alternative for older patients and for others who are no longer eligible for or do not want systemic chemotherapy. (See
         <a class="local">
          'Bendamustine plus rituximab'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For symptomatic patients relapsing less than three years after systemic chemotherapy, we suggest a BTK inhibitor. BTK inhibitors are highly effective and well-tolerated treatments. (See
         <a class="local">
          'Bruton tyrosine kinase inhibitors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For symptomatic patients with WM progression despite initial therapy with a BTK inhibitor, we offer systemic chemotherapy as given for previously untreated disease. If the patient is not able to tolerate systemic chemotherapy, we usually offer off-label treatment with
         <a class="drug drug_general" data-topicid="107696" href="/z/d/drug information/107696.html" rel="external">
          venetoclax
         </a>
         or a next generation BTK inhibitor (eg,
         <a class="drug drug_general" data-topicid="140692" href="/z/d/drug information/140692.html" rel="external">
          pirtobrutinib
         </a>
         ) as used for multiply relapsed WM, although data on this approach are limited.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3413096903">
         <span class="h2">
          Multiply relapsed disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of multiply relapsed disease is individualized based on prior therapy received, general health status, and comorbidities. Options include the off-label use of
         <a class="drug drug_general" data-topicid="107696" href="/z/d/drug information/107696.html" rel="external">
          venetoclax
         </a>
         , bortezomib-based regimens, nucleoside analog-based regimens, and other investigational therapies. High-dose chemotherapy followed by autologous hematopoietic cell transplantation (HCT) is rarely used for the treatment of WM.
        </p>
        <p class="headingAnchor" id="H2319913626">
         <span class="h3">
          Venetoclax
         </span>
         <span class="headingEndMark">
          —
         </span>
         Limited data suggest activity of
         <a class="drug drug_general" data-topicid="107696" href="/z/d/drug information/107696.html" rel="external">
          venetoclax
         </a>
         in WM. While there are not direct comparisons with other regimens, the generally well-tolerated toxicity profile and high response rates favor its use over that of bortezomib-based regimens and nucleoside analog-based regimens.
        </p>
        <p>
         A phase II study evaluated up to 24 months of
         <a class="drug drug_general" data-topicid="107696" href="/z/d/drug information/107696.html" rel="external">
          venetoclax
         </a>
         in 32 patients with relapsed or refractory WM after a median of two prior therapies [
         <a href="#rid83">
          83
         </a>
         ]. The overall response rate was 84 percent with no complete responses (CRs). Median progression-free survival (PFS) was 30 months. There was a rapid decline of PFS following treatment discontinuation at month 24, suggesting that continued therapy is likely required to maintain disease control. Six patients developed grade 4 neutropenia, one had febrile neutropenia, and one had laboratory tumor lysis syndrome.
        </p>
        <p class="headingAnchor" id="H326943736">
         <span class="h3">
          Bortezomib, dexamethasone, and rituximab
         </span>
         <span class="headingEndMark">
          —
         </span>
         While
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         has activity in WM, it is associated with clinically significant rates of peripheral neuropathy. In addition, changes in serum IgM levels may not be reflective of a response in the bone marrow in a small portion of patients treated with bortezomib [
         <a href="#rid84">
          84,85
         </a>
         ].
        </p>
        <p>
         The following prospective trials have evaluated
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         with or without
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         in WM:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A phase II trial of
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         plus
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         with or without
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         in 23 patients with symptomatic, previously untreated WM found overall and major response rates of 96 and 83 percent, respectively [
         <a href="#rid36">
          36
         </a>
         ]. Peripheral neuropathy was the most common toxicity with 69 percent of patients developing neuropathy that impaired function. Mandatory prophylactic antiviral therapy was added to the treatment protocol after four of the first seven patients developed herpes zoster. None of the patients who took antiviral prophylaxis developed herpes zoster.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A multicenter phase II trial of
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         plus
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         with or without
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         in 59 patients with symptomatic, previously untreated WM reported an overall response rate of 85 percent (3 percent complete) with most patients demonstrating an initial response at three months [
         <a href="#rid40">
          40,86
         </a>
         ]. Median PFS was 43 months. Overall survival (OS) at seven years was 66 percent. Toxicity resulted in treatment discontinuation in 27 percent. The rate of peripheral neuropathy of any grade was 46 percent (7 percent severe). The lower rate of severe neuropathy may reflect the use of subcutaneous rather than intravenous bortezomib in this trial.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another phase II study, once weekly
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         was combined with
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , which was given weekly during cycles 1 and 4 [
         <a href="#rid87">
          87
         </a>
         ]. Among 37 patients treated for relapsed or refractory WM, a minor response or better (ie, 25 percent or greater reduction in monoclonal protein levels) was seen in 81 percent of patients, including two CRs. The median time to progression was 16 months. Using this weekly schedule of bortezomib, grade 3 neurotoxicity was observed in only two cases (5 percent).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4270481746">
         <span class="h3">
          Nucleoside analog-based regimens
         </span>
         <span class="headingEndMark">
          —
         </span>
         Purine nucleoside analogs (eg,
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          fludarabine
         </a>
         and
         <a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">
          cladribine
         </a>
         ) and alkylating agents (eg,
         <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">
          chlorambucil
         </a>
         ) are treatment options for patients with multiply relapsed and refractory WM with a good performance status. These agents are moderately toxic and associated with a risk of stem cell damage, risk of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), and a higher risk of transformation [
         <a href="#rid12">
          12,88,89
         </a>
         ].
        </p>
        <p>
         A single-institution retrospective analysis of 439 patients with WM who received nucleoside analog-containing regimens (193 patients), regimens that did not contain nucleoside analogs (136 patients), or observation alone (110 patients) reported a higher combined rate of transformation to an aggressive lymphoma (Richter syndrome), myelodysplasia, or acute leukemia in patients who received nucleoside analog-based therapy (6.2 versus 0.4 percent, respectively) after a median follow-up of five years [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         Data on regimens using nucleoside analogs are described below:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cladribine plus rituximab – A phase II trial of four monthly cycles of combination therapy with
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         (dose: 375 mg/m
         <sup>
          2
         </sup>
         day 1) plus subcutaneous
         <a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">
          cladribine
         </a>
         (dose: 0.1 mg/kg day 1 through 5) in 29 patients with newly diagnosed or previously treated WM reported overall and complete response rates of 90 and 24 percent, respectively [
         <a href="#rid90">
          90
         </a>
         ]. The median time to best response was four months. The most common toxicities were neutropenia and anemia. These were generally mild with 10 episodes and 1 episode of severe (grade 3/4) neutropenia and anemia, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fludarabine plus rituximab – A prospective, multicenter trial evaluated treatment with six cycles of
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          fludarabine
         </a>
         (dose: 25 mg/m
         <sup>
          2
         </sup>
         per day for five days) plus eight weekly infusions of
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         (dose: 375 mg/m
         <sup>
          2
         </sup>
         per week) in 43 patients with WM who had received less than two prior therapies [
         <a href="#rid91">
          91
         </a>
         ]. The overall response rate was 95 percent (2 percent complete). The median time to best response and time to progression were 19 and 51 months, respectively. Severe toxicities included neutropenia (27 patients), thrombocytopenia (seven patients), and pneumonia (six patients). After a median follow-up of 40.3 months, there were three patients with transformation to aggressive lymphoma and three cases of MDS/AML. After three cases of herpes zoster were noted in the first 21 patients, prophylaxis with
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         or
         <a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">
          famciclovir
         </a>
         was given to subsequent patients until one year after treatment cessation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fludarabine plus cyclophosphamide and rituximab – In a prospective, multicenter Italian trial, 43 patients with symptomatic WM were treated with
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         (dose: 375 mg/m
         <sup>
          2
         </sup>
         on day 1) plus
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          fludarabine
         </a>
         (dose: 25 mg/m
         <sup>
          2
         </sup>
         on days 2 through 4) and
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         (dose: 250 mg/m
         <sup>
          2
         </sup>
         on days 2 through 4), administered every 28 days for up to six cycles [
         <a href="#rid92">
          92
         </a>
         ]. Prophylaxis with
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         and
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         were mandatory. The overall response rate was 79 percent (12 percent complete) with a median time to 25 and 50 percent reductions in serum monoclonal protein of two and three months, respectively. The median event-free survival was 50 months. Severe (grade 3/4) toxicities included neutropenia, which was seen in 88 percent of patients and was prolonged in 44 percent.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H28254076">
         <span class="h3">
          Other investigational agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Agents under study, both as single agents and in combinations, include next generation BTK inhibitors (eg,
         <a class="drug drug_general" data-topicid="140692" href="/z/d/drug information/140692.html" rel="external">
          pirtobrutinib
         </a>
         ),
         <a class="drug drug_general" data-topicid="105607" href="/z/d/drug information/105607.html" rel="external">
          ixazomib
         </a>
         ,
         <a class="drug drug_general" data-topicid="9523" href="/z/d/drug information/9523.html" rel="external">
          ofatumumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="91388" href="/z/d/drug information/91388.html" rel="external">
          obinutuzumab
         </a>
         , CXCR4 antagonists (
         <a class="drug drug_general" data-topicid="9517" href="/z/d/drug information/9517.html" rel="external">
          plerixafor
         </a>
         , ulocuplumab),
         <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">
          daratumumab
         </a>
         , and
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         . As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ixazomib
         </strong>
         – A phase II study evaluated the oral proteasome inhibitor
         <a class="drug drug_general" data-topicid="105607" href="/z/d/drug information/105607.html" rel="external">
          ixazomib
         </a>
         in combination with
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         (IRD) in 26 patients with symptomatic, previously untreated WM [
         <a href="#rid93">
          93,94
         </a>
         ]. The overall response rate was 96 percent, and the major response rate was 77 percent with a median time to response of eight weeks. At a median follow-up of 52 months, all patients were alive, and the median PFS was 40 months. There were no grade 4 adverse events. Grade 3 adverse events included infection (2 patients), hyperglycemia (2 patients), infusion reactions (2 patients), and neuropathy (1 patient). In another phase I/II study of IRD in 59 patients with WM, the overall response rate was 71 percent, and the estimated two-year PFS and OS were 56 and 88 percent, respectively [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Daratumumab
         </strong>
         – A small, multicenter phase II trial of single-agent
         <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">
          daratumumab
         </a>
         in patients with previously treated WM reported an overall response rate of 23 percent and a median PFS of two months [
         <a href="#rid96">
          96
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Carfilzomib
         </strong>
         <strong>
          ,
         </strong>
         <strong>
          rituximab
         </strong>
         <strong>
          ,
         </strong>
         <strong>
          dexamethasone
         </strong>
         <strong>
          (CaRD)
         </strong>
         – A phase II trial of CaRD in 31 patients with symptomatic WM who had not received prior
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         or
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         reported an overall response rate of 87 percent (1 complete) [
         <a href="#rid97">
          97
         </a>
         ]. The median times to first and best response were 2 and 13 months, respectively. At a median follow-up of 15 months, 20 patients remained free of progression. The most common severe (grade 3/4) toxicities were hyperglycemia (77 percent), elevated serum lipase (42 percent), and rituximab-related infusion reactions (19 percent). Mild to moderate peripheral neuropathy (all grade 1/2) was seen in 19 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunomodulatory drugs
         </strong>
         – A prospective phase II trial of
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         plus
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         in 35 patients with symptomatic WM, naïve to either agent, reported overall and major response rates of 72 and 64 percent, respectively [
         <a href="#rid98">
          98
         </a>
         ]. Neuropathy was the dose-limiting toxicity, and 11 patients developed neuropathy that impaired function (≥grade 2). This neuropathy resolved with cessation of therapy in 10 of these patients at a median of 6.7 months. Dose reductions were required in all patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Of note, a prospective phase II trial of the thalidomide-analog
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         plus
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         was halted due to a high rate of rapid-onset severe anemia [
         <a href="#rid99">
          99
         </a>
         ]. As such, the combination of lenalidomide plus rituximab is
         <strong>
          not
         </strong>
         recommended for the treatment of WM outside of a clinical trial.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Hematopoietic cell transplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         High-dose chemotherapy followed by autologous HCT is rarely used for the treatment of WM. Treatment-related mortality appears to be less than 10 percent, and autologous HCT may be able to produce long-term responses even in heavily pretreated patients [
         <a href="#rid100">
          100-105
         </a>
         ]. Different conditioning regimens have been proposed, but none has demonstrated superior efficacy over another. With available treatment options, the role of autologous HCT in WM is limited, and it is reserved for selected patients with good performance status in whom other treatment options have been exhausted. Allogeneic HCT carries a much higher risk of nonrelapse mortality (NRM) and should
         <strong>
          not
         </strong>
         be considered outside the context of a clinical trial [
         <a href="#rid82">
          82,102,104,106-108
         </a>
         ].
        </p>
        <p>
         Data regarding the efficacy of HCT in WM come from a meta-analysis of 15 retrospective studies that included 278 patients who underwent autologous HCT and 311 patients who underwent allogeneic HCT across several decades [
         <a href="#rid109">
          109
         </a>
         ]. All patients undergoing allogeneic HCT and most patients undergoing autologous HCT had relapsed or refractory disease. Most studies reported OS, PFS, and relapse rates (RR) at three to five years and NRM at one year. Pooled estimates were as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Autologous HCT – OS 76 percent (95% CI 65-86 percent), PFS 55 percent (95% CI 42-68 percent), RR 42 percent (95% CI 30-55 percent), and NRM 4 percent (95% CI 1-7 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Allogeneic HCT – OS 57 percent (95% CI 50-65 percent), PFS 49 percent (95% CI 42-56 percent), NRM 29 percent (95% CI 23-34 percent), RR 23 percent (95% CI 18-28 percent). Acute graft-versus-host disease (GVHD) was reported in 71 percent and usually grade I to II. Chronic GVHD was reported in 51 percent. Results following allogeneic HCT were heterogeneous, likely reflecting diversity in conditioning regimens, donor type, stem cell source, and GVHD prophylaxis used at different institutions and across time.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most patients treated with modern therapy, WM is an indolent disease with a median survival over 10 years [
         <a href="#rid110">
          110-112
         </a>
         ]. Many patients will die of causes other than WM, especially those diagnosed in older age [
         <a href="#rid113">
          113
         </a>
         ]. However, this is a heterogeneous group, and outcomes are variable.
        </p>
        <p>
         A number of multivariate models have been proposed to assess survival in this disorder [
         <a href="#rid114">
          114-120
         </a>
         ]. Many use similar clinical and laboratory variables in different combinations, and it is not clear if any of these models is superior to another. Poor prognostic factors that are common to most of these systems include older age, cytopenias, and an elevated beta-2 microglobulin level (B2M). In addition, initial studies suggest that patients with a high von Willebrand factor antigen level have shorter survival [
         <a href="#rid121">
          121
         </a>
         ].
        </p>
        <p>
         We calculate the revised International Prognostic Staging System for WM (revised IPSSWM) to assess prognosis at initiation of first therapy as follows [
         <a href="#rid122">
          122
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age &lt;65: 0 points; 66 to 75: 1 point; &gt;75: 2 points
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         B2M &gt;4 mg/L: 1 point
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lactate dehydrogenase &gt;250 IU/L: 1 point
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum albumin &lt;3.5 g/dL: 1 point
        </p>
        <p>
        </p>
        <p>
         The total points assigned stratifies patients into the following risk groups, which have differing estimated 3-year, WM-associated death rates and 10-year overall survival (OS) rates following treatment with chemoimmunotherapy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         0 points (very low risk; 3-year deaths 0 percent; 10-year OS 84 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         1 point (low risk; 3-year deaths 10 percent; 10-year OS 59 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         2 points (intermediate risk; 3-year deaths 14 percent; 10-year OS 37 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         3 points (high risk; 3-year deaths 38 percent; 10-year OS 19 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         4 to 5 points (very high risk; 3-year deaths 48 percent; 10-year OS 9 percent)
        </p>
        <p>
        </p>
        <p>
         The current survival rates are likely better than what was observed when this prognostic index was developed, since it predated the incorporation of Bruton tyrosine kinase (BTK) inhibitors. The IPSSWM has not been validated in patients treated with BTK inhibitors.
        </p>
        <p>
         Other studies have noted the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A prospective multicenter observational study created a staging system for WM utilizing serum B2M level, hemoglobin (Hb) concentration, and serum IgM concentration [
         <a href="#rid8">
          8
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Stage A (low risk) – B2M &lt;3 mg/L and Hb ≥12 g/dL
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Stage B (medium risk) – B2M &lt;3 mg/L and Hb &lt;12 g/dL
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Stage C (medium risk) – B2M ≥3 mg/L and serum IgM ≥4 g/dL
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Stage D (high risk) – B2M ≥3 mg/L and IgM &lt;4 g/dL
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Five-year rates of OS for patients with stage A, B, C, or D disease were 87, 63, 53, and 21 percent, respectively. Rates of five-year progression-free survival were 83, 55, 33, and 12 percent, respectively. Stage D patients had a significantly higher incidence of anemia, hypoalbuminemia, lymphadenopathy, and hepatosplenomegaly than those in other stages.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A 10-year follow-up of this cohort identified elevated serum lactate dehydrogenase levels as a poor prognostic factor with value added to both the original model and the IPSSWM described above [
         <a href="#rid6">
          6
         </a>
         ]. In addition, there appeared to be a subset of patients with "smoldering macroglobulinemia" who had an excellent prognosis without treatment. (See
         <a class="local">
          'Asymptomatic patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a Swedish population-based study of 1555 patients with WM or lymphoplasmacytic lymphoma diagnosed from 1980 to 2005, relative survival rates (RSR) at five years compared with the general population improved sequentially from 1980 to 1985 (RSR 0.57; 95% CI 0.46-0.68) to 2001 to 2005 (RSR 0.78; 95% CI 0.71-0.85) [
         <a href="#rid123">
          123
         </a>
         ]. Similarly, an analysis of the United States SEER database that included 2696 patients with WM diagnosed from 1988 to 2005 reported a decline in death rates with each five-year calendar period (hazard ratio [HR] 0.90; 95% CI 0.84-0.96) [
         <a href="#rid124">
          124
         </a>
         ]. This improvement in survival appeared to be driven by large improvements in younger patients. The decrease in death rates was greatest in patients &lt;50 years (HR 0.70; 95% CI 0.58-0.84). While the estimated five-year survival for the entire cohort was 52 percent, this varied dramatically by age: 71 percent in patients &lt;70 years and 39 percent in older patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Analyses of the SEER database evaluated over 6000 patients with WM diagnosed between 1980 and 2010 [
         <a href="#rid125">
          125,126
         </a>
         ]. In these studies, the relative as well as the OS of patients with WM improved in the period 2001 to 2010 when compared with previous years. In a multivariate analysis, older age, male sex, and Black ethnicity were independent adverse prognostic factors for survival. The rate of WM-related death at 10 years ranged from 10 to 20 percent, and the median OS was estimated at nine years.
        </p>
        <p>
        </p>
        <p>
         Patients with WM have a different microribonucleic acid (RNA) expression pattern when compared with healthy subjects [
         <a href="#rid127">
          127
         </a>
         ]. MicroRNAs are short, noncoding RNAs that downregulate gene expression in many tumor types and also play a role in regulating normal physiologic processes. MicroRNA expression may be involved in the pathogenesis of WM, and expression levels may differ among patients of different IPSS risk groups. More studies are required to further evaluate the prognostic potential of microRNAs in WM.
        </p>
        <p class="headingAnchor" id="H865114821">
         <span class="h1">
          CLINICAL TRIALS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzRV8srxVomMWotD038y2Xv&amp;TOPIC_ID=6654" target="_blank">
          www.clinicaltrials.gov
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H6404116">
         <span class="h1">
          WEBSITES FOR ADDITIONAL INFORMATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinicians and/or their patients may search for additional information concerning the treatment of WM on various websites. The following are listed:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The National Cancer Institute provides information for clinicians and patients. Information concerning WM can be found at its website [
         <a href="#rid128">
          128
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The International Waldenström's Macroglobulinemia Foundation has a website and provides information to patients with WM, friends, caregivers, and members of the medical profession [
         <a href="#rid129">
          129
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H757176342">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119645.html" rel="external">
          "Society guideline links: Waldenström macroglobulinemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1979263850">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/116766.html" rel="external">
          "Patient education: Waldenström macroglobulinemia (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H28">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications for treatment
         </strong>
         – Many patients with Waldenström macroglobulinemia (WM) are asymptomatic (ie, "smoldering" WM) and can be observed for months or years after the diagnosis is established before requiring treatment  (
         <a class="graphic graphic_algorithm graphicRef97649" href="/z/d/graphic/97649.html" rel="external">
          algorithm 1
         </a>
         ). There is no clear advantage to early therapy. (See
         <a class="local">
          'Asymptomatic patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Indications for treatment include  (
         <a class="graphic graphic_table graphicRef97667" href="/z/d/graphic/97667.html" rel="external">
          table 1
         </a>
         ) (see
         <a class="local">
          'Indications for treatment'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The presence of systemic symptoms (eg, weakness, fever, night sweats, fatigue, weight loss) along with physical findings (eg, symptomatic lymphadenopathy, hepatomegaly, and/or splenomegaly) and/or cytopenias (eg, anemia, thrombocytopenia, neutropenia).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Signs and symptoms due to the presence of hyperviscosity (eg, oronasal bleeding, blurred vision, headaches, dizziness, paresthesias, retinal vein engorgement and flame-shaped hemorrhages, papilledema, stupor and coma). Patients presenting with severe neurologic impairment, such as stupor or coma, should be treated with plasmapheresis on an
         <strong>
          emergency
         </strong>
         basis. (See
         <a class="local">
          'Symptomatic patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Presence of severe neuropathy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         While the severity of anemia and/or thrombocytopenia that merits treatment is unknown, we generally use cutoff values of hemoglobin ≤10 g/dL and platelet count ≤100,000/microL. Asymptomatic patients are followed periodically with complete blood counts and monoclonal protein levels. (See
         <a class="local">
          'Asymptomatic patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Emergency management of hyperviscosity
         </strong>
         – For patients who present with symptoms due to hyperviscosity or who develop hyperviscosity during treatment, we recommend the immediate institution of therapeutic plasmapheresis rather than systemic therapy alone (
         <a class="grade" href="https:///uptodate/show/grade_3" rel="external">
          Grade 1C
         </a>
         ). Plasmapheresis is widely accepted as the standard of care in this setting and is associated with a decrease in serum viscosity, an increase in capillary blood flow, and improvement in the clinical manifestations of hyperviscosity. Chemotherapy alone does not have a rapid enough onset to prevent severe outcomes. Red blood cell transfusions should be avoided, if possible, prior to plasmapheresis since they might further increase serum viscosity. Once plasmapheresis is completed, patients will need to initiate treatment to control the malignant clone. (See
         <a class="local">
          'Emergency management of hyperviscosity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial therapy
         </strong>
         – There is no standard therapy for the treatment of WM. While various drugs and combinations have demonstrated clinical benefit in prospective trials, these have not been compared directly in randomized trials. In addition, individual trials have used different response criteria, thereby making it difficult to compare these agents or regimens based on response rates alone.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For most patients with WM requiring treatment, we suggest
         <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">
          bendamustine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         (BR) rather than a Bruton tyrosine kinase (BTK) inhibitor  (
         <a class="graphic graphic_algorithm graphicRef97649" href="/z/d/graphic/97649.html" rel="external">
          algorithm 1
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). BR is administered intravenously over a short, defined course (four to six months) with an acceptable toxicity profile. (See
         <a class="local">
          'Bendamustine plus rituximab'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A BTK inhibitor is an appropriate alternative for older patients and for others who are not eligible for or do not want systemic chemotherapy. BTK inhibitors are well-tolerated oral drugs that are administered daily until progression. While we prefer to reserve these agents for the treatment or relapsed or refractory WM, other experts advocate for their more widespread use as initial therapy. (See
         <a class="local">
          'Bruton tyrosine kinase inhibitors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Single-agent
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         is no longer used routinely for WM, particularly if the IgM level is &gt;4000 mg/dL. It is less effective than other treatment options and frequently results in a transient increase in serum IgM level (IgM flare) that may lead to complications of hyperviscosity. (See
         <a class="local">
          'Limited role for single-agent rituximab'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Relapsed disease
         </strong>
         – The choice of therapy for patients with relapsed disease is dependent upon the duration of remission from their most recent therapy:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For symptomatic patients relapsing more than three years following BR, we suggest that the original treatment be repeated first (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Treatment of relapsed or refractory disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For symptomatic patients relapsing less than three years after BR, we suggest
         <a class="drug drug_general" data-topicid="126183" href="/z/d/drug information/126183.html" rel="external">
          zanubrutinib
         </a>
         rather than other therapies (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Treatment of relapsed or refractory disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Although we typically use BR as initial treatment, some patients will receive a BTK inhibitor as initial treatment. For such patients who experience progression, we offer systemic chemotherapy as given for previously untreated disease. If the patient is not able to tolerate systemic chemotherapy, we usually offer off-label treatment with
         <a class="drug drug_general" data-topicid="107696" href="/z/d/drug information/107696.html" rel="external">
          venetoclax
         </a>
         or a next generation BTK inhibitor (eg,
         <a class="drug drug_general" data-topicid="140692" href="/z/d/drug information/140692.html" rel="external">
          pirtobrutinib
         </a>
         ) as used for multiply relapsed WM, although data on this approach are limited. (See
         <a class="local">
          'Multiply relapsed disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The role of high-dose chemotherapy followed by autologous hematopoietic cell transplantation in WM is limited, and it is reserved for selected patients with good performance status in whom other treatment options have been exhausted. (See
         <a class="local">
          'Hematopoietic cell transplantation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3409259145">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Robert A Kyle, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Minnema MC, Kimby E, D'Sa S, et al. Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. Haematologica 2017; 102:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pophali PA, Bartley A, Kapoor P, et al. Prevalence and survival of smouldering Waldenström macroglobulinaemia in the United States. Br J Haematol 2019; 184:1014.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kyle RA, Benson JT, Larson DR, et al. Progression in smoldering Waldenstrom macroglobulinemia: long-term results. Blood 2012; 119:4462.
          </a>
         </li>
         <li class="breakAll">
          https://www.nccn.org/professionals/physician_gls/pdf/waldenstroms.pdf (Accessed on November 16, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gobbi PG, Baldini L, Broglia C, et al. Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance? Clin Cancer Res 2005; 11:1786.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dhodapkar MV, Hoering A, Gertz MA, et al. Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003. Blood 2009; 113:793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baldini L, Goldaniga M, Guffanti A, et al. Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. J Clin Oncol 2005; 23:4662.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dhodapkar MV, Jacobson JL, Gertz MA, et al. Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood 2001; 98:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kyle RA, Benson J, Larson D, et al. IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström's macroglobulinemia. Clin Lymphoma Myeloma 2009; 9:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ansell SM, Kyle RA, Reeder CB, et al. Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc 2010; 85:824.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zanwar S, Abeykoon JP, Ansell SM, et al. Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia. Br J Haematol 2021; 195:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leleu X, Soumerai J, Roccaro A, et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. J Clin Oncol 2009; 27:250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bustoros M, Sklavenitis-Pistofidis R, Kapoor P, et al. Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. J Clin Oncol 2019; 37:1403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Sa S, Kersten MJ, Castillo JJ, et al. Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel. Br J Haematol 2017; 176:728.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castillo JJ, Advani RH, Branagan AR, et al. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. Lancet Haematol 2020; 7:e827.
          </a>
         </li>
         <li class="breakAll">
          https://www.msmart.org/wm-treatment-guidelines (Accessed on September 07, 2021).
         </li>
         <li class="breakAll">
          https://www.nccn.org/professionals/physician_gls/pdf/waldenstroms.pdf (Accessed on September 07, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pratt G, El-Sharkawi D, Kothari J, et al. Diagnosis and management of Waldenström macroglobulinaemia-A British Society for Haematology guideline. Br J Haematol 2022; 197:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buske C, Castillo JJ, Abeykoon JP, et al. Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients. Semin Hematol 2023; 60:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Treon SP. How I treat Waldenström macroglobulinemia. Blood 2015; 126:721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Connelly-Smith L, Alquist CR, Aqui NA, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. J Clin Apher 2023; 38:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szczepiorkowski ZM, Winters JL, Bandarenko N, et al. Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2010; 25:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reinhart WH, Lutolf O, Nydegger UR, et al. Plasmapheresis for hyperviscosity syndrome in macroglobulinemia Waldenström and multiple myeloma: influence on blood rheology and the microcirculation. J Lab Clin Med 1992; 119:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Höffkes HG, Heemann UW, Teschendorf C, et al. Hyperviscosity syndrome: efficacy and comparison of plasma exchange by plasma separation and cascade filtration in patients with immunocytoma of Waldenström's type. Clin Nephrol 1995; 43:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menke MN, Feke GT, McMeel JW, Treon SP. Effect of plasmapheresis on hyperviscosity-related retinopathy and retinal hemodynamics in patients with Waldenstrom's macroglobulinemia. Invest Ophthalmol Vis Sci 2008; 49:1157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stone MJ, Bogen SA. Evidence-based focused review of management of hyperviscosity syndrome. Blood 2012; 119:2205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           SCHWAB PJ, FAHEY JL. Treatment of Waldenstrom's macroglobulinemia by plasmapheresis. N Engl J Med 1960; 263:574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           SCHWAB PJ, OKUN E, FAHEY JL. Reversal of retinopathy in Waldenstrom's macroglobulinemia by plasmapheresis. A report of two cases. Arch Ophthalmol 1960; 64:515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reynolds WA. Late report of the first case of plasmapheresis for Waldenström's Macroglobulinemia. JAMA 1981; 245:606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buske C, Hoster E, Dreyling M, et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia 2009; 23:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:3383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381:1203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kapoor P, Ansell SM, Fonseca R, et al. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. JAMA Oncol 2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tedeschi A, Picardi P, Ferrero S, et al. Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia. Leuk Lymphoma 2015; 56:2637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 2007; 25:3344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol 2009; 27:3830.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghobrial IM, Xie W, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia. Am J Hematol 2010; 85:670.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agathocleous A, Rohatiner A, Rule S, et al. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia. Br J Haematol 2010; 151:346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dimopoulos MA, García-Sanz R, Gavriatopoulou M, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood 2013; 122:3276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laribi K, Poulain S, Willems L, et al. Bendamustine plus rituximab in newly-diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO). Br J Haematol 2019; 186:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin P, Chen Z, Cheson BD, et al. Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma. Br J Haematol 2017; 178:250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rummel MJ, Lerchenmuller C, Hensel M, et al. Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial). Blood (ASH Annual Meeting Abstracts) 2019; 134:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tam CS, Opat S, D'Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood 2020; 136:2038.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dimopoulos MA, Opat S, D'Sa S, et al. Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study. J Clin Oncol 2023; 41:5099.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shadman M, Flinn IW, Levy MY, et al. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study. Lancet Haematol 2023; 10:e35.
          </a>
         </li>
         <li class="breakAll">
          https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213217Orig1s004lbl.pdf (Accessed on September 07, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dimopoulos M, Sanz RG, Lee HP, et al. Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. Blood Adv 2020; 4:6009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trotman J, Opat S, Gottlieb D, et al. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood 2020; 136:2027.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Treon SP, Meid K, Gustine J, et al. Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. J Clin Oncol 2021; 39:565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cao Y, Hunter ZR, Liu X, et al. CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells. Br J Haematol 2015; 168:701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castillo JJ, Sarosiek SR, Gustine JN, et al. Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy. Blood Adv 2022; 6:1015.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buske C, Tedeschi A, Trotman J, et al. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study. J Clin Oncol 2022; 40:52.
          </a>
         </li>
         <li class="breakAll">
          Ibrutinib capsules. United States prescribing information. Revised January 2017. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205552s016lbl.pdf (Accessed on May 18, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia. N Engl J Med 2018; 378:2399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lampson BL, Yu L, Glynn RJ, et al. Ventricular arrhythmias and sudden death in patients taking ibrutinib. Blood 2017; 129:2581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caron F, Leong DP, Hillis C, et al. Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis. Blood Adv 2017; 1:772.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abeykoon JP, Zanwar S, Ansell SM, et al. Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. Br J Haematol 2020; 188:394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gustine JN, Meid K, Dubeau T, et al. Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound. Am J Hematol 2018; 93:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castillo JJ, Gustine JN, Meid K, et al. Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia. Haematologica 2018; 103:e307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med 2015; 372:1430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Treon SP, Xu L, Hunter Z. MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia. N Engl J Med 2015; 373:584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dimopoulos MA, Trotman J, Tedeschi A, et al. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol 2017; 18:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Treon SP, Gustine J, Meid K, et al. Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia. J Clin Oncol 2018; 36:2755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trotman J, Buske C, Tedeschi A, et al. Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial. Clin Cancer Res 2021; 27:5793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castillo JJ, Meid K, Gustine JN, et al. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia 2022; 36:532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castillo JJ, Itchaki G, Paludo J, et al. Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. Blood 2019; 133:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Owen RG, McCarthy H, Rule S, et al. Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematol 2020; 7:e112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buske C, Dimopoulos MA, Grunenberg A, et al. Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia. J Clin Oncol 2023; 41:2607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paludo J, Abeykoon JP, Kumar S, et al. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia. Br J Haematol 2017; 179:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenström's macroglobulinemia with rituximab. J Clin Oncol 2002; 20:2327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Treon SP, Agus DB, Link B, et al. CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia. J Immunother (1991) 2001; 24:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dimopoulos MA, Alexanian R, Gika D, et al. Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progression. Leuk Lymphoma 2004; 45:2057.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gertz MA, Rue M, Blood E, et al. Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 2004; 45:2047.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Treon SP, Branagan AR, Hunter Z, et al. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Ann Oncol 2004; 15:1481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghobrial IM, Fonseca R, Greipp PR, et al. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer 2004; 101:2593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castillo JJ, Kanan S, Meid K, et al. Rituximab intolerance in patients with Waldenström macroglobulinaemia. Br J Haematol 2016; 174:645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Treon SP, Tedeschi A, San-Miguel J, et al. Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria. Semin Hematol 2023; 60:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Banwait R, O'Regan K, Campigotto F, et al. The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia. Am J Hematol 2011; 86:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castillo JJ, Gustine J, Meid K, et al. Histological transformation to diffuse large B-cell lymphoma in patients with Waldenström macroglobulinemia. Am J Hematol 2016; 91:1032.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Durot E, Tomowiak C, Michallet AS, et al. Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO). Br J Haematol 2017; 179:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dimopoulos MA, Kastritis E, Owen RG, et al. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood 2014; 124:1404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castillo JJ, Allan JN, Siddiqi T, et al. Venetoclax in Previously Treated Waldenström Macroglobulinemia. J Clin Oncol 2022; 40:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Treon SP, Hunter ZR, Matous J, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res 2007; 13:3320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strauss SJ, Maharaj L, Hoare S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 2006; 24:2105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gavriatopoulou M, García-Sanz R, Kastritis E, et al. BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. Blood 2017; 129:456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghobrial IM, Hong F, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010; 28:1422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tournilhac O, Cazin B, Leprètre S, et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 2004; 103:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dimopoulos MA, Zervas C, Zomas A, et al. Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia. Clin Lymphoma 2002; 3:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laszlo D, Andreola G, Rigacci L, et al. Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study. J Clin Oncol 2010; 28:2233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Treon SP, Branagan AR, Ioakimidis L, et al. Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood 2009; 113:3673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tedeschi A, Benevolo G, Varettoni M, et al. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer 2012; 118:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castillo JJ, Meid K, Gustine JN, et al. Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia. Clin Cancer Res 2018; 24:3247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castillo JJ, Meid K, Flynn CA, et al. Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up. Blood Adv 2020; 4:3952.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kersten MJ, Amaador K, Minnema MC, et al. Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study. J Clin Oncol 2022; 40:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castillo JJ, Libby EN, Ansell SM, et al. Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia. Blood Adv 2020; 4:5089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Treon SP, Tripsas CK, Meid K, et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia. Blood 2014; 124:503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Treon SP, Soumerai JD, Branagan AR, et al. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 2008; 112:4452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Treon SP, Soumerai JD, Branagan AR, et al. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res 2009; 15:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Desikan R, Dhodapkar M, Siegel D, et al. High-dose therapy with autologous haemopoietic stem cell support for Waldenström's macroglobulinaemia. Br J Haematol 1999; 105:993.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martino R, Shah A, Romero P, et al. Allogeneic bone marrow transplantation for advanced Waldenstrom's macroglobulinemia. Bone Marrow Transplant 1999; 23:747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anagnostopoulos A, Hari PN, Pérez WS, et al. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia. Biol Blood Marrow Transplant 2006; 12:845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson LD, Sandmaier BM, Maris MB, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation (HCT) for refractory Waldenstrom's macroglobulinemia (WM): Evidence for a graft-versus-WM effect (abstract). Blood 2006; 108:862a.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garnier A, Robin M, Larosa F, et al. Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenström’s macroglobulinemia. Results of a retrospective analysis of the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Haematologica 2010; 95:950.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kyriakou C, Canals C, Sibon D, et al. High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010; 28:2227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kyriakou C, Canals C, Taghipour G, et al. Allogeneic stem cell transplantation in Waldenstrom macroglobulinemia: An analysis of 106 cases from the European Bone Marrow Registry (abstract). Haematologica 2007; 92(suppl):WM3.9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maffini E, Anderson LD Jr, Sandmaier BM, et al. Non-myeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory Waldenström macroglobulinemia: evidence for a graft-versus-lymphoma effect. Haematologica 2018; 103:e252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kyriakou C, Canals C, Cornelissen JJ, et al. Allogeneic stem-cell transplantation in patients with Waldenström macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010; 28:4926.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parrondo RD, Reljic T, Iqbal M, et al. Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Waldenström Macroglobulinemia: A Systematic Review and Meta-analysis. Clin Lymphoma Myeloma Leuk 2020; 20:e694.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buske C, Sadullah S, Kastritis E, et al. Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review. Lancet Haematol 2018; 5:e299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brandefors L, Melin B, Lindh J, et al. Prognostic factors and primary treatment for Waldenström macroglobulinemia - a Swedish Lymphoma Registry study. Br J Haematol 2018; 183:564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amaador K, Kersten MJ, Visser O, et al. Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population-based study in the Netherlands, 1989-2018. Br J Haematol 2022; 196:660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalal NH, Dores GM, Curtis RE, et al. Cause-specific mortality in individuals with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia, 2000-2016. Br J Haematol 2020; 189:1107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Facon T, Brouillard M, Duhamel A, et al. Prognostic factors in Waldenström's macroglobulinemia: a report of 167 cases. J Clin Oncol 1993; 11:1553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gobbi PG, Bettini R, Montecucco C, et al. Study of prognosis in Waldenström's macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility. Blood 1994; 83:2939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morel P, Monconduit M, Jacomy D, et al. patients with the description of a new scoring system and its validation on 253 other patients. Blood 2000; 96:852.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merlini G, Baldini L, Broglia C, et al. Prognostic factors in symptomatic Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghobrial IM, Fonseca R, Gertz MA, et al. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol 2006; 133:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 2009; 113:4163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dimopoulos MA, Kastritis E, Delimpassi S, et al. The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens. Haematologica 2008; 93:1420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hivert B, Caron C, Petit S, et al. Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstrom macroglobulinemia. Blood 2012; 120:3214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kastritis E, Morel P, Duhamel A, et al. A revised international prognostic score system for Waldenström's macroglobulinemia. Leukemia 2019; 33:2654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kristinsson SY, Eloranta S, Dickman PW, et al. Patterns of survival in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005. Am J Hematol 2013; 88:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sekhar J, Sanfilippo K, Zhang Q, et al. Waldenström macroglobulinemia: a Surveillance, Epidemiology, and End Results database review from 1988 to 2005. Leuk Lymphoma 2012; 53:1625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castillo JJ, Olszewski AJ, Kanan S, et al. Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database. Br J Haematol 2015; 169:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castillo JJ, Olszewski AJ, Cronin AM, et al. Survival trends in Waldenström macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database. Blood 2014; 123:3999.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roccaro AM, Sacco A, Chen C, et al. microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia. Blood 2009; 113:4391.
          </a>
         </li>
         <li class="breakAll">
          Search under Plasma cell neoplasms at: www.cancer.gov www.cancer.gov (Accessed on June 29, 2017).
         </li>
         <li class="breakAll">
          https://www.iwmf.com/ (Accessed on June 29, 2017).
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6654 Version 78.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27758817" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29532912" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Prevalence and survival of smouldering Waldenström macroglobulinaemia in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22451426" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Progression in smoldering Waldenstrom macroglobulinemia: long-term results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22451426" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Progression in smoldering Waldenstrom macroglobulinemia: long-term results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15756000" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18931340" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16034042" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11418461" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19362962" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström's macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20702770" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34340248" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19064987" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30990729" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28198999" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33091356" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33091356" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33091356" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35020191" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Diagnosis and management of Waldenström macroglobulinaemia-A British Society for Haematology guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37099027" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26002963" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : How I treat Waldenström macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37017433" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20568098" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1727909" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Plasmapheresis for hyperviscosity syndrome in macroglobulinemia Waldenström and multiple myeloma: influence on blood rheology and the microcirculation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7634550" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Hyperviscosity syndrome: efficacy and comparison of plasma exchange by plasma separation and cascade filtration in patients with immunocytoma of Waldenström's type.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18326744" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Effect of plasmapheresis on hyperviscosity-related retinopathy and retinal hemodynamics in patients with Waldenstrom's macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22147890" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Evidence-based focused review of management of hyperviscosity syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14443924" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Treatment of Waldenstrom's macroglobulinemia by plasmapheresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13749036" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Reversal of retinopathy in Waldenstrom's macroglobulinemia by plasmapheresis. A report of two cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6779021" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Late report of the first case of plasmapheresis for Waldenström's Macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18818699" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15908650" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23433739" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28056114" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25651423" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17577016" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19506160" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20652865" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20880120" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17353550" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24004667" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30548257" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Bendamustine plus rituximab in newly-diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28419413" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32731259" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37478390" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36400069" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36400069" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33284944" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32698195" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32931398" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25371371" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34965304" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34606378" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34606378" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29856685" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28223277" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Ventricular arrhythmias and sudden death in patients taking ibrutinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29296721" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31468508" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29280186" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29472352" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25853747" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Ibrutinib in previously treated Waldenström's macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26244327" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27956157" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30044692" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34380643" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34531537" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30523119" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31866281" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36763945" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28786474" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11981004" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Treatment of Waldenström's macroglobulinemia with rituximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11395644" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15370250" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15370249" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15367407" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15493038" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26523929" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Rituximab intolerance in patients with Waldenström macroglobulinaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37173155" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21681781" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27415417" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Histological transformation to diffuse large B-cell lymphoma in patients with Waldenström macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28770576" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25027391" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34793256" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Venetoclax in Previously Treated Waldenström Macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17545538" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16606971" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27872060" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20142586" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12969985" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12521393" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20368573" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19015393" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21732338" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29661775" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32822482" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34388022" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33085756" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24859363" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18713945" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Thalidomide and rituximab in Waldenstrom macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19118065" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10554812" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : High-dose therapy with autologous haemopoietic stem cell support for Waldenström's macroglobulinaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10218857" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Allogeneic bone marrow transplantation for advanced Waldenstrom's macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16864055" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Nonmyeloablative allogeneic hematopoietic cell transplantation (HCT) for refractory Waldenstrom's macroglobulinemia (WM): Evidence for a graft-versus-WM effect (abstract)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20081058" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenström’s macroglobulinemia. Results of a retrospective analysis of the SociétéFrançaise de Greffe de Moelle et de Thérapie Cellulaire.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20368570" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Allogeneic stem cell transplantation in Waldenstrom macroglobulinemia: An analysis of 106 cases from the European Bone Marrow Registry (abstract)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29545343" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Non-myeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory Waldenström macroglobulinemia: evidence for a graft-versus-lymphoma effect.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20956626" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Allogeneic stem-cell transplantation in patients with Waldenström macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32616401" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Waldenström Macroglobulinemia: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29958569" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30198549" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Prognostic factors and primary treatment for Waldenström macroglobulinemia - a Swedish Lymphoma Registry study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34605017" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population-based study in the Netherlands, 1989-2018.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32090327" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Cause-specific mortality in individuals with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia, 2000-2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8336194" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Prognostic factors in Waldenström's macroglobulinemia: a report of 167 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8180389" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Study of prognosis in Waldenström's macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10910896" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : patients with the description of a new scoring system and its validation on 253 other patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12720138" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Prognostic factors in symptomatic Waldenstrom's macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16611306" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19196866" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : International prognostic scoring system for Waldenstrom macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18641029" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22896002" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstrom macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31118465" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : A revised international prognostic score system for Waldenström's macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23165980" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Patterns of survival in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22239669" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Waldenström macroglobulinemia: a Surveillance, Epidemiology, and End Results database review from 1988 to 2005.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25521528" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24948623" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Survival trends in Waldenström macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19074725" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
